Top 10 Regulatory Services Companies in Apac – 2023
Life sciences companies have a deep-rooted process for clinical development, but the outbreak of the pandemic has disrupted the traditional ways of testing new drugs. As the post-pandemic era continues to unravel the limiting scopes of clinical studies, life sciences companies keep expanding their search for other possibilities and devise new ways of working with accelerated digital adoption and innovation, particularly to refine their approach to regulatory requirements.
Real-world data (RWD) is becoming increasingly important in the regulatory demands of life sciences companies. In the past, the FDA has primarily focused on considering clinical data from controlled clinical studies when reviewing and approving drugs. However, the FDA is now recognizing the value of RWD in monitoring post-market safety, adverse events, and making judicious regulatory decisions.
Equally interesting is the use of Pragmatic clinical trials (PCTs) in improving regulatory needs by providing a more efficient and effective way to generate timely evidence to guide drug approvals, especially during pandemics like COVID-19. These patient-centred, outcome-based trials compare the benefits and risks of therapeutic interventions to inform clinical and policy decision-making. These trends are driving the life sciences market to grow at a CAGR of 8.7 percent.
To put the spotlight on the key developments, Life Sciences Review APAC illustrates how companies are leveraging the latest developments in the regulatory services space to give value-based solutions to their customers. This edition also features leadership articles from Philippe Pinton, VP, Global Head Translational Medicine and Clinical Pharmacology, Ferring Pharmaceuticals; Jon Kallay, Senior Technology and Market Development Manager at Charles River Laboratories; Joel Finkle, Associate Director, Regulatory Information Management, BeiGene USA; Narayana Rao, Vice President of Biopharma, Asia Pacific Middle-East Africa, Avantor. They shed light on how the rapid emergence of cell and gene therapy (CGT) has offered hope for the treatment of both rare and common genetic disorders as well as previously incurable life-threatening diseases.
In this edition of Life Sciences Review APAC, we also bring the stories of the most successful companies in the regulatory services domain. In the list, Critical Compliance particularly stands out for offering quality and regulatory consulting services to organizations of all sizes in manufacturing and distribution and assisting them in achieving compliance goals.
Through the following pages, we aim to highlight the innovative trends and latest developments in the regulatory services space. We would like to know your thoughts.
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Regulatory Services Companies in Apac
